Synspira’s PAAG15A receives orphan drug designation for cystic fibrosis treatment
Synspira Therapeutics’ investigational inhaled treatment, PAAG15A, has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of cystic fibrosis. PAAG15A, also known as SNSP113, is under development by Synspira Therapeutics as an innovative inhaled therapy designed to enhance lung function in patients with cystic fibrosis. This drug targets […]